Jefferies Financial Group Inc. Acquires New Shares in Masimo Co. (NASDAQ:MASI)

Jefferies Financial Group Inc. acquired a new position in shares of Masimo Co. (NASDAQ:MASI - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,657 shares of the medical equipment provider's stock, valued at approximately $1,762,000.

Several other institutional investors also recently modified their holdings of the stock. FMR LLC grew its position in shares of Masimo by 19.8% during the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock worth $1,338,509,000 after buying an additional 1,340,836 shares during the period. Vanguard Group Inc. grew its position in shares of Masimo by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after purchasing an additional 66,215 shares during the period. Capital Research Global Investors grew its position in shares of Masimo by 80.5% in the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after purchasing an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Masimo by 119.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after acquiring an additional 943,001 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its position in Masimo by 8.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider's stock worth $274,791,000 after acquiring an additional 135,888 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on MASI shares. BTIG Research set a $193.00 price target on Masimo and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and set a $200.00 price target (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Wells Fargo & Company reduced their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Raymond James reduced their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Masimo has a consensus rating of "Moderate Buy" and an average price target of $191.60.

Insiders Place Their Bets

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Bilal Muhsin sold 10,000 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at $3,946,804.16. The trade was a 29.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,053 shares of company stock worth $6,998,565 in the last 90 days. Company insiders own 9.70% of the company's stock.

Masimo Stock Performance

MASI traded up $1.23 during trading hours on Friday, reaching $155.62. The company's stock had a trading volume of 537,620 shares, compared to its average volume of 653,640. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The company's 50-day moving average is $160.06 and its 200-day moving average is $167.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market cap of $8.44 billion, a PE ratio of 107.32 and a beta of 1.23.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. During the same quarter in the previous year, the company posted $0.77 earnings per share. The business's revenue was down 24.5% on a year-over-year basis. On average, equities analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.